Litigation and Corporate & Securities partner Robert Heim has been retained as counsel for Generex Biotechnology Corporation as part of Generex’s review of recent irregular trading activity in its stock. Robert has been retained to evaluate the company’s claims and legal remedies that stem from Generex’s asset acquisition from Veneto Holdings LLC.

Generex Biotechnology is publicly traded integrated healthcare holding company with end-to-end solutions for patient-centric care from rapid diagnosis through delivery of personalized therapies.

Robert’s involvement is featured in the Yahoo Finance article, “Genrex Biotechnology Issues Shareholder Alert.”